Scientific Publications & Collaborations

COLLABORATIONS

View More

  • University of Alberta, Alberta, Canada
  • Mount Sinai Hospital, Ontario, Canada
  • Michael’s Hospital, Ontario, Canada
  • University of Toronto, Ontario, Canada
  • Centre for Addiction and Mental Health , Ontario, Canada
  • Sunnybrook Health Sciences Centre, Ontario, Canada
  • Hospital for Sick Children, Ontario, Canada
  • York University, Ontario, Canada
  • London Health Sciences Centre, Ontario, Canada
  • Centre Hospitalier Universitaire de Sherbrooke, Quebec, Canada
  • Dalhousie University, Nova Scotia, Canada
  • Hamilton Health Sciences, Ontario, Canada
  • University of British Columbia, British Columbia, Canada
  • McGill University, Quebec, Canada
  • University Health Network (UHN), Ontario, Canada
  • Mount Sinai Hospital, Ontario, Canada
  • Queens University, Ontario, Canada
  • Université de Montréal, Quebec, Canada
  • University of Manitoba, Manitoba, Canada
  • Women’s College Hospital, Ontario, Canada
  • Cancer Genomics Research Laboratory (CGR), Rockville, Maryland, USA
  • NCI Frederick National Laboratory for Cancer Research, Bethesda, Maryland, USA
  • Leidos Biomedical Research, Inc., Bethesda, Maryland, USA
  • Radboud University Medical Center, Nijmegen, Netherlands
  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
  • Spanish National Cancer Research Centre, Madrid, Spain
  • Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, Cambridge, UK
  • Northwestern University, Illinois, USA
  • Wake Forest University, North Carolina, USA
  • Vancouver Prostate Centre, British Columbia, Canada
  • BC Cancer, Vancouver, British Columbia, Canada
  • BERG, Framingham, MA, USA
  • Impact Genetics, Ontario, Canada
  • Gamma Dynacare & Panacea Global, Ontario, Canada
  • Color Genomics, Burlingame, CA, USA
  • GlaxoSmithKline, London, UK
  • Nucleix, Tel Aviv, Israel
  • ProteoMedix, Schlieren, Switzerland
  • miR Scientific Inc. New York, USA
  • Allergan, New Jersey, USA.
  • Kinghorn Cancer Centre, Sydney, Australia
  • Garvan Institute of Medical Research, Sydney, Australia
  • Renji Hospital, Shanghai, China
  • National Institute of Public Health in Mexico, Merida, Mexico.
  • DeCODE Genetics, Reykjavík, Iceland
  • Metabolomic Technologies Inc., Alberta, Canada
  • POINT Biopharma, Indianapolis, Indiana, USA
  • BioImmuno Diagnostics Inc, Ontario Canada
  • Alphalaboratories, Ontario, Canada

SCIENTIFIC PUBLICATIONS

View More

  1. Kiebish MA, Tekumalla P, Ravipaty S, Dobi A, Srivastava S, Wu W, Patil S, Friss T, Klotz A, Srinivasan A, Cullen J, Rosner IL, Ali A, Laszlo S, Petrovic M, Fleshner N, Garren J, Miller G, Mahaveer Chand N, Rodrigues LO, Granger E, Kellogg MD, Luan S, Diamandis E, Akmaev VR, Sarangarajan R, Bountra C, Freedland SJ, McLeod DG, Narain NR. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia. Sci Rep. 2021 Jul 23;11(1):15052. doi: 10.1038/s41598-021-94438-4. PMID: 34302010; PMCID: PMC8302659.
  2. Goldberg H, Glicksman R, Woon D, Hoffman A, Shaikh H, Chandrasekar T, Klaassen Z, Wallis CJD, Ahmad AE, Sanmamed-Salgado N, Qu X, Moraes FY, Diamandis EP, Berlin A, Fleshner NE. Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer? BJU Int. 2021 Jun;127(6):654-664. doi: 10.1111/bju.15236. Epub 2020 Sep 26. PMID: 32926761
  3. Wagner, H., Kenk, M., Fraser, M., Berlin, A., & Fleshner, N. (2021). Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus. doi:10.1016/j.euf.2021.06.002
  4. Hubbell, E., Clarke, C. A., Aravanis, A. M., & Berg, C. D. (2020). Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiology Biomarkers & Prevention. doi:10.1158/1055-9965.epi-20-1134
  5. Bolanos, A., Bhimani, A., Paul, S., Kenk, M., Nguyen, S., Avgoustis, A., . . . Mcgarvey, D. (2020). Act Local, Think Global! The First ISBER-UHN Virtual Symposium. Biopreservation and Biobanking, 18(6), 592-593. doi:10.1089/bio.2020.29078.ajb
  6. Peter, M. R., Bilenky, M., Isserlin, R., Bader, G. D., Shen, S. Y., Carvalho, D. D., Hansen, A., Joshua, A., Hirst, M., Fleshner, N., Bapat, B. (2020). Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. Epigenomics. 2020 Sep 01 issn1750-1911. doi:10.1101/2020.04.08.032565
  7. Fachiroh, J., Addai, B. W., Xu, X., Ezzat, S., Wagner, H., Marques, M. M., & Yadav, B. K. (2020). The Responses of Biobanks to COVID-19 (913780511 718685825 M. K. Henderson & 913780512 718685825 Z. Kozlakidis, Eds.). Biopreservation and Biobanking, 16(6). 2020 Aug 31.  doi:10.1089/bio.2020.29074.mkh
  8. Woon, D. T., Herrera-Cáceres, J. O., Goldberg, H., Shiakh, H., Whelan, E., Nason, G., . . . Fleshner, N. (2020). A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens. Journal of Urology, 204(2), 289-295. doi:10.1097/ju.0000000000000808
  9. Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C., & Seiden, M. V. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology, 31(6), 745–759. doi: https://doi.org/10.1016/j.annonc.2020.02.011na
  10. Hermanns T, Savio AJ, Olkhov-Mitsel E, Mari A, Wettstein MS, Saba K, Bhindi B, Kuk C, Poyet C, Wild PJ, Noon A, Bashir S, Juvet T, Rendon RA, Waltregny D, van der Kwast T, Finelli A, Kulkarni GS, Fleshner NE, Lo K, Bapat B, Zlotta AR. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grad Urol Oncol. 2020 Feb 18. pii: S1078-1439(20)30008-9. doi: 10.1016/j.urolonc.2020.01.007. [Epub ahead of print] PubMed PMID: 32081560.
  11. Lipunova, N., Wesselius, A., Cheng, K. K., Schooten, F. V., Bryan, R. T., Cazier, J., . . . Zeegers, M. P. (2019). Genome-wide Association Study for Tumour Stage, Grade, Size, and Age at Diagnosis of Non–muscle-invasive Bladder Cancer. European Urology Oncology, 2(4), 381-389. doi:10.1016/j.euo.2018.08.020
  12. Mousa A, Petrovic M, Fleshner NE. Prevalence and predictors of cannabis use among men receiving androgen-deprivation therapy for advanced prostate cancer. Can Urol Assoc J. 2020 Jan;14(1):E20-E26. doi: 10.5489/cuaj.5911. Epub 2019 Jun. PubMed PMID: 31658007; PubMed Central PMCID: PMC6955174.
  13. Savio AJ, Kamdar S, Jeyapala R, Olkhov-Mitsel E, Cuizon C, Finelli A, Zlotta AR, Toi A, Fleshner NE, van der Kwast T, Bapat B. Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. J Mol Diagn. 2020 Jan;22(1):30-39. doi:10.1016/j.jmoldx.2019.08.003. Epub 2019 Oct 9. PubMed PMID: 31605802.
  14. Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, Bristow RG, Downes M, Vesprini D, Liu S, Bapat B, Boutros PC. Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome. J Natl Cancer Inst. 2020 Mar 1;112(3):247-255. doi: 10.1093/jnci/djz112. PubMed PMID: 31161221; PubMed Central PMCID: PMC7073919.
  15. Kamdar S, Isserlin R, Van der Kwast T, Zlotta AR, Bader GD, Fleshner NE, Bapat B. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z. PubMed PMID: 30917865; PubMed Central PMCID: PMC6438015.
  16. Shen, Shu Yi, et al. “Sensitive Tumour Detection and Classification Using Plasma Cell-Free DNA Methylomes.” Nature, vol. 563, no. 7732, 2018, pp. 579–583., doi:10.1038/s41586-018-0703-0.
  17. Schumacher, F.R., Al Olama, A.A., Berndt, S.I. et al.Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 50, 928–936 (2018) doi:10.1038/s41588-018-0142-8
  18. Cullen, J., Young, D., Chen, Y., Degon, M., Farrell, J., Sedarsky, J., … Sesterhenn, I. A. (2018). Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. European Urology Focus, 4(6), 818–824. doi: 10.1016/j.euf.2017.02.016
  19. Benidir, T., Hersey, K., Finelli, A., Hamilton, R., Joshua, A. M., Kulkarni, G., … Fleshner, N. (2018). Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 36(5). doi: 10.1016/j.urolonc.2018.01.011
  20. Dadaev,T., Saunders, E.J., Newcombe, P.J. et al.Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun 9, 2256 (2018) doi:10.1038/s41467-018-04109-8
  21. Fraser, M., Sabelnykova, V., Yamaguchi, T. et al.Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364 (2017) doi:10.1038/nature20788
  22. Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE, Klotz L, Vesprini D, Bapat B. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. J Urol. 2017 Feb;197(2):335-341. doi:10.1016/j.juro.2016.08.081. Epub 2016 Aug 18. PubMed PMID: 27545574.
  23. Boutros, P., Fraser, M., Harding, N. et al.Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47, 736–745 (2015) doi:10.1038/ng.3315
  24. Sayyid, R. K., Sayyid, A. K., Klaassen, Z., Hersey, K., Goldberg, H., Perlis, N., … Fleshner, N. E. (2018). Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients’ and urologic oncologists’ perspectives. Canadian Urological Association Journal, 12(5). doi: 10.5489/cuaj.4922
  25. Briollais, L., Oxcelik, H., Xu, J., Kwiatkowski, M., Fleshner, N. E., Lalonde, E., & Sendorek, D. H. (2017). RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. JNCI: Journal of the National Cancer Institute, 109(12). doi: 10.1093/jnci/djx105
  26. Sayyid, R. K., Dingar, D., Fleshner, K., Thorburn, T., Diamond, J., Yao, E., … Fleshner, N. (2017). What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy? Canadian Urological Association Journal, 11(3-4), 118. doi: 10.5489/cuaj.4182
  27. Aravanis, A. M., Lee, M., & Klausner, R. D. (2017). Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Cell, 168(4), 571–574. doi: 10.1016/j.cell.2017.01.030 Retrieved from: https://www.cell.com/cell/fulltext/S0092-8674%2817%2930115-0#relatedArticles
  28. European Association of Urology. (2017, March 27). Scientists report genetic test to help predict men at most risk from aggressive prostate cancer. ScienceDaily. Retrieved October 24, 2019 from sciencedaily.com/releases/2017/03/170327083451.htm
  29. Olkhov-Mitsel E, Siadat F, Kron K, Liu L, Savio AJ, Trachtenberg J, Fleshner N, van der Kwast T, Bapat B. Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. Oncol Letters. 2017, in press.
  30. Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah YJ, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. J Natl Cancer Inst 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258. PubMed PMID: 28376164.
  31. Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, Hermanns T, Fleshner NE, va Rhijn BW, van der Kwast TH, Zlotta AR, Bapat B. Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. Transl Oncol. 2017 Apr;10(2):168-177. doi: 10.1016/j.tranon.2017.01.001.Epub 2017 Feb 3. PubMed PMID: 28167242; PubMed Central PMCID: PMC5293735.
  32. Poudineh, M., Aldridge, P. M., Ahmed, S., Green, B. J., Kermanshah, L., Nguyen, V., … Kelley, S. O. (2016). Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. Nature Nanotechnology, 12(3), 274–281. doi: 10.1038/nnano.2016.239
  33. Sayyid, R. K., Evans, A., Hersey, K., Maloni, R., Hurtado-Coll, A., Kulkarni, G., … Fleshner, N. E. (2016). A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. Clinical Cancer Research, 23(8), 1974–1980. doi: 10.1158/1078-0432.ccr-16-1790
  34. Kamdar SN, Ho LT, Kron KJ, Isserlin R, van der Kwast T, Zlotta AR, Fleshner NE, Bader G, Bapat B. Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate Clin Epigenetics. 2016 Mar 15;8:32. doi: 10.1186/s13148-016-0195-4. eCollection 2016. PubMed PMID: 26981160; PubMed Central PMCID: PMC4791926.
  35. Lichner, Z., Ding, Q., Samaan, S., Saleh, C., Nasser, A., Al-Haddad, S., … Yousef, G. M. (2015). miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. The Journal of Pathology, 237(2), 226–237. doi: 10.1002/path.4568
  36. Mora BC, Fleshner NE, Klotz LH, Venkateswaran V. The effects of serum from prostate cancer patients with elevated body mass index on prostate cancer cells in vitro. Lipid Insights. 2015; 8:11-19. doi:10.4137/LPI.S23135.
  37. Kader AK, Liss MA, Trottier G, et al.Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk. Urology. 2015;85(1):165-170. doi: 10.1016/j.urology.2014.07.081.
  38. Bhindi, B., Locke, J., Alibhai, S. M., Kulkarni, G. S., Margel, D. S., Hamilton, R. J., … Fleshner, N. E. (2015). Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. European Urology, 67(1), 64–70. doi: 10.1016/j.eururo.2014.01.040
  39. Lichner Z, Ding Q, Samaan S, Saleh C, Nasser A, Al-Haddad S, Samuel JN, Fleshner NE, Stephan C, Jung K, Yousef GM. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways. J Pathol. 2015 Oct;237(2):226-37. doi: 10.1002/path.4568. Epub 2015 Jul 24. PubMed PMID: 26011734.
  40. Fleshner, N. E., & Bhindi, B. (2014). Metabolic syndrome and diabetes for the urologist. Canadian Urological Association Journal, 8(7-8), 159. doi: 10.5489/cuaj.2314
  41. White-Al Habeeb NMA, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, Jovanovic L, Fleshner N, van der Kwast T, Nelson CC, Bapat B.Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget. 2014;5(17):7858-7869.
  42. Skeldon, S. C., Simmons, A., Hersey, K., Finelli, A., Jewett, M. A., Zlotta, A. R., & Fleshner, N. E. (2014). Lean Methodology Improves Efficiency in Outpatient Academic Uro-oncology Clinics. Urology, 83(5), 992–998. doi: 10.1016/j.urology.2013.11.048
  43. Olkhov-Mitsel E, Zdravic D, Kron K, van der Kwast T, Fleshner N, Bapat B. Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. Sci Rep. 2014;4:4432.
  44. Briollais, L., Xu, J., Kwiatkowski, M., Friedlander, M., Recker, F., Kuk, C., … Ozcelik, H. (2014). MP49-20 Fine-Mapping Of The Kallikrein Region And Its Role In Prostate Cancer Aggressiveness: Results From A Canadian Cohort And The European Randomized Study For Prostate Cancer Screening. Journal of Urology, 191(4S). doi: 10.1016/j.juro.2014.02.1121
  45. Bhindi B, Margel D, Hamilton RJ, et al. The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. Urology. 2014;84(5):1073-1080. doi:10.1016/j.urology.2014.05.071.
  46. Bhindi B, Kulkarni GS, Finelli A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol. 2014;66(5):841-848. doi:10.1016/j.eururo.2014.06.005.
  47. Joshua, A. M., Zannella, V. E., Downes, M. R., Bowes, B., Hersey, K., Koritzinsky, M., … Pollak, M. (2014). A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer and Prostatic Diseases, 17(3), 252–258. doi: 10.1038/pcan.2014.20
  48. Neuzillet Y, van Rhijn BW, Prigoda NL, Bapat B, Liu L, Bostrom PJ, Fleshner NE, Gallie BL, Zlotta AR, Jewett MA, van der Kwast TH. FGFR3 mutations, but no FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. Virchows Arch. 2014 Aug;465(2):207-13. doi:10.1007/s00428-014-1596-4. Epub 2014 Jun 1. PubMed PMID: 24880661.
  49. Lichner, Z., Fendler, A., Saleh, C., Nasser, A. N., Boles, D., Al-Haddad, S., … Yousef, G. M. (2013). MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer. Clinical Chemistry, 59(11), 1595–1603. doi: 10.1373/clinchem.2013.205450
  50. Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, Jung K, Stephan C, Fleshner NE, Yousef GM. MicroRNA signature helps distinguish early from late biochemical failure in prostate Clin Chem. 2013 Nov;59(11):1595-603. doi: 10.1373/clinchem.2013.205450 Epub 2013 Aug 19. PubMed PMID: 23958847.
  51. Novak A, Binnington B, Ngan B, Chadwick K, Fleshner N, Lingwood CA. Cholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies. Glycobiology. 2013;23(11):1230-1239. doi:10.1093/glycob/cwt059.
  52. Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, Bapat B. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res. 2013;19(13):3450-3461.
  53. Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, Shariat SF, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013 Feb;63(2):379-85. doi:10.1016/j.eururo.2012.07.047. Epub 2012 Aug 2. PubMed PMID: 22883484.
  54. van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der Kwast TH, Zlotta AR. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int. 2012 Oct;110(8):1169-76. doi: 1111/j.1464-410X.2012.10996.x. Epub 2012 Mar 27. PubMed PMID: 22448597.
  55. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, Bapat B, van der Kwast T. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res. 2012;18(10):2896-2904.
  56. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Zlotta AR, Bapat B. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187(1):310-314.
  57. Olkhov-Mitsel E, van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics. 2012;7(9):1037-1045.
  58. Venkateswaran, S., Margel, D., Yap, S., Hersey, K., Yip, P., & Fleshner, N. E. (2012). Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate. Canadian Urological Association Journal, 6(3), 183–186. doi: 10.5489/cuaj.11278
  59. Bhindi, B., Trottier, G., Elharram, M., Fernandes, K. A., Lockwood, G., Toi, A., … Fleshner, N. E. (2012). Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU International, 110(7), 980–986. doi: 10.1111/j.1464-410x.2012.10957.
  60. Margel, D., Yap, S. A., Lawrentschuk, N., Klotz, L., Haider, M., Hersey, K., … Fleshner, N. (2012). Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study. Journal of Urology, 187(4), 1247–1252. doi: 10.1016/j.juro.2011.11.112
  61. Singh, D. K., Hersey, K., Perlis, N., Crook, J., Jarvi, K., & Fleshner, N. (2012). The Effect of Radiation on Semen Quality and Fertility in Men Treated With Brachytherapy for Early Stage Prostate Cancer. Journal of Urology, 187(3), 987–989. doi: 10.1016/j.juro.2011.10.141
  62. Margel, D., Bostrom, P., Baniel, J., Yossepowitch, O., Zlotta, A., & Fleshner, N. (2012). External Validation of a Biomarker Based Pre-Cystectomy Algorithm to Predict Nonorgan Confined Urothelial Cancers. Journal of Urology, 187(3), 840–844. doi: 10.1016/j.juro.2011.10.148
  63. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011;129(10);2454-2462.
  64. Kron KJ, Liu L, Pethe V, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, van der Kwast TH, Bapat B. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest. 2010;90(7):1060-1067.
  65. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A, Venkateswaran V, Pinthus J, Fleshner N, van der Kwast T, Bapat B. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One. 2009;4(3):e4830.
  66. Fleshner, N. E., & Lawrentschuk, N. (2009). Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers. Urology, 73(5). doi: 10.1016/j.urology.2009.02.022
  67. Volpe, A., & Jewett, M. A. S. (2005). The natural history of small renal masses. Nature Clinical Practice Urology , 2(8), 384–390. doi: 10.1038/ncpuro0254